InvestorsHub Logo
Followers 0
Posts 7710
Boards Moderated 0
Alias Born 05/05/2020

Re: None

Friday, 02/25/2022 11:34:10 AM

Friday, February 25, 2022 11:34:10 AM

Post# of 3504
$STAB News Out - Statera Biopharma Announces Changes to Board of Directors
Satish Chandran of Lays Sciences and Physis Pharma, Inc. to join Board of Directors as Steve Barbarick transitions to advisory role—

FORT COLLINS, Colo., Feb. 25, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ: STAB) (the “Company” or “Statera Biopharma”), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced two changes to their Board of Directors. Satish Chandran, Ph.D., President and CEO of Lays Sciences, Inc. and CEO of Physis Pharma, Inc., will join the Board of Directors effective February 24, 2022. Steve Barbarick, resigned as a Director on February 21, 2022, and will continue in an advisory position.

“We are thrilled to welcome Dr. Chandran, a biotechnology veteran with more than 30 years of experience in drug, biologicals and medical device product development and commercialization, to our board at this exciting time as Statera Biopharma advances our pipeline toward several clinical milestones,” said Michael K. Handley, President and Chief Executive Officer, Statera Biopharma. “At this same time, we thank Steve Barbarick for his service. I am delighted we will continue to benefit from his expertise in his role as an advisor.”

https://finance.yahoo.com/news/statera-biopharma-announces-changes-board-123200501.html